Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Mar 2010

Akman Sezin Asik, Kose Sukran, Halicioglu Oya

Abstract excerpt

OBJECTIVE: Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the emergence of drug-resistant hepatitis B virus (HBV) in a significant number of patients with chronic hepatitis B (CHB) infection. The aim of our study was to evaluate the LAM and ADV mutations detected in our patient group. MATERIALS AND METHODS: Twenty-four patients diagnosed with CHB were enrolled in this study. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 19665408
DOI: 10.1016/j.ijid.2009.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.PMID 19665408Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

Virological response to adefovir monotherapy and the risk of adefovir resistance.Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.Semantic proximity Read ↗

Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.Semantic proximity Read ↗

Virologic response and resistance to adefovir in patients with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.